Capdevila J, et al. - In this prospective, multicenter, single-arm phase II EVERLAR study, researchers intended to confirm the already established antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with neuroendocrine tumors (NETs). They administered everolimus 10 mg/day and the SSA octreotide 30 mg every 28 days in patients with advanced nonfunctioning well-differentiated gastrointestinal NETs (GI-NETs) that progressed in the last 12 months. Similar to the results of RADIANT-2 in functioning setting, findings of this study demonstrated the clinically relevant efficacy of everolimus-octreotide combination in nonfunctioning GI-NETs